Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,235 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Dentin Hypersensitivity
Interventions: KH001, Placebo; Drug
Lead sponsor: HysensBio Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Cambridge, Massachusetts

Conditions: Early Alzheimer's Disease
Interventions: MK-2214, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 36
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 32 more

Conditions: Systemic Sclerosis, Diffuse Scleroderma
Interventions: Privigen; Biological
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Rhinitis, Allergic, Seasonal
Interventions: GW685698X Aqueous Nasal Spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Woodstock, Georgia

Conditions: Lupus Nephritis
Interventions: Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 28
States / cities: Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more

Conditions: Headache
Interventions: Placebo, Propranolol, Amitriptyline, Topiramate; Drug
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Asthma
Interventions: Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 75
States / cities: Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more

Conditions: HIV Infections
Interventions: VH3739937, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Bakersfield, California • Miami, Florida • Dallas, Texas

Conditions: Schizophrenia
Interventions: PF-06412562 3mg BID, PF-06412562 9mg BID, PF-06412562 45mg BID, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Arcadia, California • Glendale, California • Baltimore, Maryland + 2 more

Conditions: Tourette Syndrome
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Long Beach, California • National City, California • San Bernardino, California + 27 more

Conditions: Obesity
Interventions: RGT001-075, Placebo; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Los Angeles, California • Valparaiso, Indiana • Omaha, Nebraska + 7 more

Conditions: Fractures
Interventions: Teriparatide, Placebo; Drug
Lead sponsor: Ohio Orthopedic Center of Excellence; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Upper Arlington, Ohio

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more

Conditions: Crohn Disease
Interventions: Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg); Biological
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar; Drug
Lead sponsor: Epitopoietic Research Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 3
States / cities: Orange, California • Boston, Massachusetts

Conditions: Sporadic Inclusion Body Myositis
Interventions: BYM338/bimagrumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 36 Years to 85 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Orange, California • Sacramento, California + 8 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Mepolizumab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 88
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more

Conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions: RBS2418, Placebo; Drug
Lead sponsor: Riboscience, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Newark, Delaware • Las Vegas, Nevada • Nashville, Tennessee + 1 more

Conditions: Ulcerative Colitis
Interventions: PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 60
States / cities: Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more

Conditions: Palliative Care, Pain, Cancer
Interventions: Sativex Low Dose, Sativex Medium Dose, Sativex High Dose; Drug
Lead sponsor: GW Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Tuscaloosa, Alabama • Casa Grande, Arizona • Fountain Valley, California + 19 more

Conditions: Scoliosis
Interventions: Tranexamic Acid, Normal Saline, Epsilon aminocaproic acid; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 10 Years to 80 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Postoperative, Premature Infant, Opioid Use
Interventions: Acetaminophen, Saline; Drug
Lead sponsor: St. Louis University; Other
Eligibility: Up to 1 Month
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Phase 2 Study of KH001 in Long-term Relief From Dentin Hypersensitivity

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

IVIG Treatment in Systemic Sclerosis

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

Medical Therapies for Chronic Post-Traumatic Headaches

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

RSV-F Vaccine Dose Ranging Study in Young Women

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.

Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery

Postoperative Pain Control & Relief in Neonates